NewswireToday - /newswire/ -
Bagsvaerd, Denmark, 2008/12/19 - Novozymes Biopolymer, part of Novozymes, world leader in bio-innovation, today announced winning the Gold Innovation Award at CPhI worldwide conference in Frankfurt, Germany, for its novel form of hyaluronic acid (HA).
Novozymes Biopolymer, part of Novozymes, world leader in bioinnovation, today announced winning the Gold Innovation Award at CPhI worldwide conference in Frankfurt, Germany, for its novel form of hyaluronic acid (HA) HyaCare®. The CPhI Innovation Award is established as the showcase for exceptional work in developing research and technology, setting the standards for the pharmaceutical manufacturing industry. The judging panel took into account a number of factors including effective development of the technology and its key benefits to the pharmaceutical industry.
Traditionally, HA is derived from rooster combs or from strains of pathogenic Streptococcal bacteria, which allows for a high degree of contamination by animal proteins, viruses and end toxins present in the bacterial genome. HyaCare is developed under animal-free conditions with no animal derived ingredients used at any stage of the manufacturing process. Novozymes Biopolymer developed this unique non-pathogenic method for producing HA by fermentation of a novel production strain, Bacillus subtilis. The Bacillus strain is a well-characterised, endotoxin free organism that is generally regarded as safe by the US Food and Drug Administration (FDA).
Animal-free ingredients offer an ethical, safe solution for the production of ingredients that form the basis of biological products. Popularity of these ingredients is increasing as regulatory authorities begin to enforce strict quality measures on products to improve safety, particularly with potential contamination risks from pathogens such as viruses in animal-derived ingredients.
HyaCare is produced using Novozymes Biopolymer patented, advanced and safe fermentation and purification technology which results in a completely pure product. While both rooster comb and Streptococcus derived HAs must be recovered using powerful organic solvents, this product is secreted outside the bacterial cell and can be collected using only water, eliminating the need for organic solvents. HyaCare is used for a wide range of solubility applications in the pharmaceutical sector, including ophthalmology, wound healing and osteoarthritis as well as in cosmetics and anti-wrinkle creams.
“HyaCare is a breakthrough in safety and purity and we are delighted to have won the gold award in recognition of this,” explains Kim Budolph Johansen, Global Business Manager at Novozymes A/S. “HyaCare is the world's first hyaluronic acid that is 100% free of animal-derived raw materials and organic solvent remnants and as such has many advantages over existing methods of manufacture.”
Novozymes is the world leader in bioinnovation. Together with customers across a broad array of industries, we create tomorrow’s industrial biosolutions, improving our customers' business and the use of our planet's resources.
With over 700 products used in 130 countries, Novozymes’ bioinnovations improve industrial performance and safeguard the world’s resources by offering superior and sustainable solutions for tomorrow’s ever-changing marketplace.
Novozymes’ natural solutions enhance and promote everything from removing trans-fats in food, to advancing biofuels to power the world tomorrow. Our never-ending exploration of nature’s potential is evidenced by over 4,500 patents, showing what is possible when nature and technology join forces.
Our 4,500+ employees working in research, production and sales around the world are committed to shaping business today and our world tomorrow.
Detailed descriptions of the Company and its products and services can be viewed on the Company's website.
Novozymes Biopharma UK Ltd
Sally Kent, Marketing Manager
T: +44 115 9551209